Acesso livre
Acesso livre

Infectologia

Artigo | Tuberculose em tempos de COVID-19.

15 Fev, 2022 | 11:50h

Tuberculosis in times of COVID-19 – Journal of Epidemiology & Community Health

Conteúdos relacionados:

Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.

Global tuberculosis progress reversed by COVID-19 pandemic.

WHO Report: Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic.

How COVID is derailing the fight against HIV, TB and malaria.

How COVID hurt the fight against other dangerous diseases

World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis

WHO: Benefits of continuing to provide life-saving HIV services outweigh the risk of COVID-19 transmission by 100 to 1

Tuberculosis and Covid-19: Fighting a deadly syndemic

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

Por que a maioria das pessoas com COVID não precisa ser testada pelos próximos 30 dias, mesmo em caso de reexposição?

15 Fev, 2022 | 11:49h

Why don’t most people with COVID need to test for another 30 days, even if they’re re-exposed? – The Conversation

Coorte retrospectiva | Associação da infecção pelo SARS-CoV-2 com morbidade e mortalidade maternas graves de complicações obstétricas.

15 Fev, 2022 | 11:47h

Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications – JAMA

Comunicado de imprensa: NIH-funded study suggests COVID-19 increases risk of pregnancy complications – NIH News Releases

 

Comentário no Twitter

 

Vacinas cujo alvo é a variante Ômicron não são melhores do que as vacinas originais em testes preliminares feitos em animais.

15 Fev, 2022 | 11:46h

Omicron-targeted vaccines do no better than original jabs in early tests – Nature

Cientistas deliberadamente contaminaram pessoas com COVID– Aqui está o que aprenderam.

15 Fev, 2022 | 11:45h

Scientists deliberately gave people COVID — here’s what they learnt – Nature

Estudo original: [Preprint] Results from the first Covid-19 human challenge study (deliberately infecting individuals in a controlled environment).

Conteúdos relacionados:

Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.

World’s first coronavirus “Human Challenge” study receives ethics approval in the UK  (vários textos sobre o tema)

Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.

Metanálise de estudos clínicos randomizados | Vacinas para prevenir COVID-19.

15 Fev, 2022 | 11:43h

Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials – PLOS One

Revisão sistemática | Eficácia das terapias antivirais para COVID-19.

15 Fev, 2022 | 11:42h

Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials – BMC Infectious Diseases

Estudo identifica fatores de risco para Covid-19 grave em crianças.

15 Fev, 2022 | 11:41h

Risk Factors for Severe COVID-19 in Children – Pediatrics

Covid-19 – Quarta dose de vacina: quem precisa dela e por quê?

15 Fev, 2022 | 11:40h

Covid-19: Fourth vaccine doses—who needs them and why? – The BMJ

Novavax afirma que vacina proteica funciona para crianças a partir dos 12 anos de idade.

14 Fev, 2022 | 16:16h

Novavax says protein vaccine works for kids as young as 12 – Associated Press

Comunicado de imprensa: Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

Conteúdos relacionados:

Randomized trial with nearly 30.000 individuals showed Novavax vaccine was safe and had an overall efficacy of 90.4% against symptomatic infections.

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.